These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20740487)

  • 1. Response to: ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation.
    McNeill A
    Mov Disord; 2010 Oct; 25(13):2253. PubMed ID: 20740487
    [No Abstract]   [Full Text] [Related]  

  • 2. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation.
    Schneider SA; Paisan-Ruiz C; Quinn NP; Lees AJ; Houlden H; Hardy J; Bhatia KP
    Mov Disord; 2010 Jun; 25(8):979-84. PubMed ID: 20310007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATP13A2-related neurodegeneration (PARK9) without evidence of brain iron accumulation.
    Chien HF; Bonifati V; Barbosa ER
    Mov Disord; 2011 Jun; 26(7):1364-5. PubMed ID: 21469196
    [No Abstract]   [Full Text] [Related]  

  • 4. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype.
    Brüggemann N; Hagenah J; Reetz K; Schmidt A; Kasten M; Buchmann I; Eckerle S; Bähre M; Münchau A; Djarmati A; van der Vegt J; Siebner H; Binkofski F; Ramirez A; Behrens MI; Klein C
    Arch Neurol; 2010 Nov; 67(11):1357-63. PubMed ID: 21060012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel mutations in ATP13A2 associated with mixed neurological presentations and iron toxicity due to nonsense-mediated decay.
    Kırımtay K; Temizci B; Gültekin M; Yapıcı Z; Karabay A
    Brain Res; 2021 Jan; 1750():147167. PubMed ID: 33091395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Parkinson-associated human P5B-ATPase ATP13A2 protects against the iron-induced cytotoxicity.
    Rinaldi DE; Corradi GR; Cuesta LM; Adamo HP; de Tezanos Pinto F
    Biochim Biophys Acta; 2015 Aug; 1848(8):1646-55. PubMed ID: 25912790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9).
    Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.
    Park JS; Sue CM
    Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype.
    Ning YP; Kanai K; Tomiyama H; Li Y; Funayama M; Yoshino H; Sato S; Asahina M; Kuwabara S; Takeda A; Hattori T; Mizuno Y; Hattori N
    Neurology; 2008 Apr; 70(16 Pt 2):1491-3. PubMed ID: 18413573
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism.
    Park JS; Mehta P; Cooper AA; Veivers D; Heimbach A; Stiller B; Kubisch C; Fung VS; Krainc D; Mackay-Sim A; Sue CM
    Hum Mutat; 2011 Aug; 32(8):956-64. PubMed ID: 21542062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From PARK9 to SPG78: The clinical spectrum of ATP13A2 mutations.
    Erro R; Picillo M; Manara R; Pellecchia MT; Barone P
    Parkinsonism Relat Disord; 2019 Aug; 65():272-273. PubMed ID: 31151786
    [No Abstract]   [Full Text] [Related]  

  • 12. Juvenile dystonia-parkinsonism syndrome caused by a novel p.S941Tfs1X ATP13A2 (PARK9) mutation.
    Martino D; Melzi V; Franco G; Kandasamy N; Monfrini E; Di Fonzo A
    Parkinsonism Relat Disord; 2015 Nov; 21(11):1378-80. PubMed ID: 26421390
    [No Abstract]   [Full Text] [Related]  

  • 13. ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons.
    Matsui H; Sato F; Sato S; Koike M; Taruno Y; Saiki S; Funayama M; Ito H; Taniguchi Y; Uemura N; Toyoda A; Sakaki Y; Takeda S; Uchiyama Y; Hattori N; Takahashi R
    FEBS Lett; 2013 May; 587(9):1316-25. PubMed ID: 23499937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motor pathway excitability in ATP13A2 mutation carriers: a transcranial magnetic stimulation study.
    Zittel S; Kroeger J; van der Vegt JP; Siebner HR; Brüggemann N; Ramirez A; Behrens MI; Gerloff C; Bäumer T; Klein C; Münchau A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):590-4. PubMed ID: 22104014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural mechanisms for gating and ion selectivity of the human polyamine transporter ATP13A2.
    Tillinghast J; Drury S; Bowser D; Benn A; Lee KPK
    Mol Cell; 2021 Nov; 81(22):4650-4662.e4. PubMed ID: 34715014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eye movement disorders in ATP13A2 mutation carriers (PARK9).
    Machner B; Sprenger A; Behrens MI; Ramirez A; Brüggemann N; Klein C; Helmchen C
    Mov Disord; 2010 Nov; 25(15):2687-9. PubMed ID: 20842691
    [No Abstract]   [Full Text] [Related]  

  • 17. ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein.
    Tsunemi T; Hamada K; Krainc D
    J Neurosci; 2014 Nov; 34(46):15281-7. PubMed ID: 25392495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants.
    Covy JP; Waxman EA; Giasson BI
    J Neurosci Res; 2012 Dec; 90(12):2306-16. PubMed ID: 22847264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms.
    Park JS; Blair NF; Sue CM
    Mov Disord; 2015 May; 30(6):770-9. PubMed ID: 25900096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kufor-Rakeb Syndrome/PARK9: One Novel and One Possible Recurring Ashkenazi ATP13A2 Mutation.
    Inzelberg R; Estrada-Cuzcano A; Laitman Y; De Vriendt E; Friedman E; Jordanova A
    J Parkinsons Dis; 2018; 8(3):399-403. PubMed ID: 29966207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.